FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 623 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant... October 4, 2024 The Galleri multi-cancer blood test: what you need to know September 13, 2021 Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole... September 24, 2021 How Having a Creative Outlet Helped Me Cope During Cancer November 8, 2022 Load more HOT NEWS Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... When You and Your Child Have VHL: 8 Ways to Cope Teen Helps Mom With Cancer Shave Her Head, Then Turns To... Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like...
